Use of Resveratrol to treat experimental multiple sclerosis
Use of Resveratrol to treat experimental multiple sclerosis
批准号:
7394180
负责人:
Prakash S Nagarkatti
金额:
$33.64万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-01 至 2012-08-31
关键词:
AcuteAddressAdjuvantAdverse effectsAffectAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryApoptosisAryl Hydrocarbon ReceptorAutoantigensAutoimmune DiseasesCD44 geneCardiovascular DiseasesCell LineCell physiologyCellsCharacteristicsChronicChronic DiseaseClinicalDemyelinationsDendritic CellsDiagnosisDioxinsDiseaseDown-RegulationElementsEncephalomyelitisEstrogen ReceptorsExhibitsExperimental Autoimmune EncephalomyelitisExposure toFunctional disorderGene ExpressionGenesGrapesHeterogeneityHomingImmune responseImmunosuppressionImmunosuppressive AgentsIn VitroInduction of ApoptosisInfiltrationInflammationInflammatoryInjection of therapeutic agentKnockout MiceLifeLuc GeneMediatingModalityMorusMultiple SclerosisMusMyelinMyelin Basic ProteinsNerve DegenerationNeuraxisParalysedPathway interactionsPeanuts - dietaryPeripheralPharmaceutical PreparationsPlantsPlayPrincipal InvestigatorPromoter RegionsPropertyProteinsProteolipidsRelapseReporterReporter GenesResveratrolRodent ModelRoleSideSite-Directed MutagenesisSymptomsT-LymphocyteTestingTherapeutic immunosuppressionTimeTransfectionUp-Regulationautocrinecyclooxygenase 2deletion analysisdisabilitydisorder controlin vivoinsightnoveloligodendrocyte-myelin glycoproteinparacrinepolyphenolpreventprogramspromoterreceptorresponsetranscription factoryoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Multiple Sclerosis (MS) is an autoimmune disease that affects ~400,000 people in the US. It is a life-long
chronic disease diagnosed primarily in young adults. There is, as yet no cure for MS. The current treatment
includes use of immunosuppressive drugs that often exhibit toxic side effects.Thus, there is a pressing need
for alternate and more effective treatment strategies that target the components of inflammatory cells. CAM
therapies constitute an important strategy to treat and control the disease. Experimental autoimmune
encephalomyelitis is an animal model of MS induced by injection of self antigens, myelin basic protein,
proteolipid protein or myelin oligodendrocyte glycoprotein and adjuvants. Resveratrol (RES; 3,5,4'-
trihydroxystilbene), a nonflovaonoid polyphenol found in various plants including mulberries, peanuts and
grapes has been shown to have beneficial effects particularly on cardiovascular diseases through its
antiinflammatory properties. Our Preliminary Studies have demonstrated that RES induces apoptosis primarily
in activated T cells through Fas-FasL interactions, involving aryl hydrocarbon receptor (AhR) and estrogen
receptor (ER). Moreover, in vivo, RES down regulates CD44 and upregulates FoxpS. We are also excited by
our findings that RES treatment decreases the inflammation and clinical symptoms of EAE. In the current
study, we will test the central hypothesis that RES treatment is effective against EAE through multiple
pathways incuding induction of apoptosis in myelin-specific T cells, suppression of DC functions, decreased
T cell infiltration in the CMS due to CD44 down-regulation on T cells, and upregulation of T regs. We will
pursue the specific aims: # 1. Study the role of Fas-FasL interactions in resveratrol (RES)-induced apoptosis
in T cells and dendritic cells (DCs) involving autocrine or paracrine path ways.#2. Investigate the role of AhR
in Fas-FasL upregulation and consequent apoptosis induced by RES in T cells.tf 3. Test the role of ER in the
induction of apoptosis in T cells and peripheral T dysfunction following RES treatment.^ 4. Study the effect of
RES on initiation and progression of EAE. These studies are aimed at providing insights into the efficacy of
RES mainly in acute, remitting-relapsing and chronic forms of the disease which represent diverse
pathological and immunological characteristics. Together, our studies should provide novel mechanistic
clues on how RES helps in the treatment of MS and develop better CAM therapies to control the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative Core
-
批准号:10428525
-
项目类别:
-
资助金额:$57.18万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Administrative Core
-
批准号:10227907
-
项目类别:
-
资助金额:$53.0万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Administrative Core
-
批准号:10830736
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for Dietary Supplements and Inflammation
-
批准号:8531296
-
项目类别:
-
资助金额:$196.18万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for Dietary Supplements and Inflammation
-
批准号:8733726
-
项目类别:
-
资助金额:$203.23万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for Dietary Supplements and Inflammation
-
批准号:8216765
-
项目类别:
-
资助金额:$200.56万
-
财政年份:2012
-
负责人:Prakash S Nagarkatti
-
依托单位:
Immunopathological basis of PTSD
-
批准号:8466380
-
项目类别:
-
资助金额:$32.97万
-
财政年份:2011
-
负责人:Prakash S Nagarkatti
-
依托单位:
Immunopathological basis of PTSD
-
批准号:8167365
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2011
-
负责人:Prakash S Nagarkatti
-
依托单位:
Immunopathological basis of PTSD
-
批准号:8662798
-
项目类别:
-
资助金额:$34.15万
-
财政年份:2011
-
负责人:Prakash S Nagarkatti
-
依托单位:
Immunopathological basis of PTSD
-
批准号:8277881
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2011
-
负责人:Prakash S Nagarkatti
-
依托单位:
Immunotoxicology Core
-
批准号:7394188
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for CAM Research on Autoimmune and Inflammatory Diseases
-
批准号:7681154
-
项目类别:
-
资助金额:$118.68万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for CAM Research on Autoimmune and Inflammatory Diseases
-
批准号:7907072
-
项目类别:
-
资助金额:$4.8万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Cannabidiol induced apoptosis in T cell to treat autoimmune hepatitis
-
批准号:7394185
-
项目类别:
-
资助金额:$33.38万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for CAM Research on Autoimmune and Inflammatory Diseases
-
批准号:7367428
-
项目类别:
-
资助金额:$120.2万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Anti-inflammatory mechanisms of American ginseng in colitis
-
批准号:7394184
-
项目类别:
-
资助金额:$28.24万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
CAM Center for Epigenetic Regulation of Inflammation
-
批准号:8739821
-
项目类别:
-
资助金额:$170.26万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for CAM Research on Autoimmune and Inflammatory Diseases
-
批准号:7921617
-
项目类别:
-
资助金额:$123.91万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
Center for CAM Research on Autoimmune and Inflammatory Diseases
-
批准号:8142730
-
项目类别:
-
资助金额:$117.97万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
CAM Center for Epigenetic Regulation of Inflammation
-
批准号:9127094
-
项目类别:
-
资助金额:$163.48万
-
财政年份:2007
-
负责人:Prakash S Nagarkatti
-
依托单位:
海外基金